/
Nephrology
Chronic Kidney Disease
105
Pipeline Programs↗
206
Active Trials↗
101
Companies Involved↗
Chronic Kidney Disease is a highly competitive landscape with 105 programs across 101 companies. The most active players are AstraZeneca, Novo Nordisk, Shaanxi Micot Pharmaceutical Technology Co., Ltd.. 20 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical64
Phase 17
Phase 214
Phase 320
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
89 of 98 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 98 classified programs, each share of the total. Modality classified for 99% of 105 pipeline programs.
Analysis
Trial Status
797
clinical trials
Completed432 · 54%
Recruiting102 · 13%
Unknown status62 · 8%
Terminated61 · 8%
Not yet recruiting57 · 7%
Active, not recruiting40 · 5%
Other43 · 5%
Clinical Trials
Trial Activity
797 trials
The Use of Risk Prediction to Identify Patients at Risk for Chronic Kidney Disease (Short Name: RISK [Risk InterventionS for Chronic Kidney Disease])
Recruiting·—·Preclinical·NCT07857200·1,500 enrolled
Page 1 of 54
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)